User profiles for Susanna A. McColley
 | Susanna A McColleyProfessor of Pediatrics, Northwestern University Feinberg School of Medicine Verified email at northwestern.edu Cited by 15949 |
[HTML][HTML] Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Background Cystic fibrosis is a life-limiting disease that is caused by defective or deficient
cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the …
cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the …
[HTML][HTML] Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation
…, N Derichs, M Howenstine, SA McColley… - The Journal of …, 2017 - Elsevier
Objective Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance
regulator (CFTR) gene, continues to present diagnostic challenges. Newborn screening and …
regulator (CFTR) gene, continues to present diagnostic challenges. Newborn screening and …
[HTML][HTML] Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children
Study objective To determine whether primary snoring (PS) could be distinguished from
childhood obstructive sleep apnea syndrome (OSAS) by clinical history. Design Retrospective …
childhood obstructive sleep apnea syndrome (OSAS) by clinical history. Design Retrospective …
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 …
Background The phe508del CFTR mutation causes cystic fibrosis by limiting the amount of
CFTR protein that reaches the epithelial cell surface. We tested combination treatment with …
CFTR protein that reaches the epithelial cell surface. We tested combination treatment with …
Clinical significance of microbial infection and adaptation in cystic fibrosis
…, M Jain, M Bar-Meir, SA McColley - Clinical microbiology …, 2011 - Am Soc Microbiol
A select group of microorganisms inhabit the airways of individuals with cystic fibrosis. Once
established within the pulmonary environment in these patients, many of these microbes …
established within the pulmonary environment in these patients, many of these microbes …
Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea
SA McColley, MM April, JL Carroll… - … –Head & Neck …, 1992 - jamanetwork.com
• A retrospective study of pediatric patients with obstructive sleep apnea who underwent
adenotonsillectomy between 1987 and 1990 was undertaken to determine the frequency of …
adenotonsillectomy between 1987 and 1990 was undertaken to determine the frequency of …
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
…, DB Rosenbluth, PA Walker, SA McColley… - The Lancet …, 2014 - thelancet.com
Background Ataluren was developed to restore functional protein production in genetic disorders
caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients…
caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients…
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
…, F Xuan, CE Wainwright, SA McColley - American journal of …, 2021 - atsjournals.org
… Correspondence and requests for reprints should be addressed to Susanna A. McColley,
MD, Ann and Robert H. Lurie Children’s Hospital of Chicago, 303 E Superior Street #205, …
MD, Ann and Robert H. Lurie Children’s Hospital of Chicago, 303 E Superior Street #205, …
[HTML][HTML] High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea
SA McColley, JL Carroll, S Curtis, GM Loughlin… - Chest, 1997 - Elsevier
Study objective To determine whether allergic sensitization occurs frequently in children with
habitual snoring and whether allergy predicts the occurrence of obstructive sleep apnea …
habitual snoring and whether allergy predicts the occurrence of obstructive sleep apnea …
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
…, J Cooke, SM Rowe, SA McColley… - The Lancet …, 2015 - thelancet.com
Background Ivacaftor has been previously assessed in patients with cystic fibrosis with
Gly551Asp-CFTR or other gating mutations. We assessed ivacaftor in patients with Arg117His-…
Gly551Asp-CFTR or other gating mutations. We assessed ivacaftor in patients with Arg117His-…